Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 90


Practical management of toxicities associated with targeted therapies for advanced gastroenteropancreatic neuroendocrine tumors.

Cuyle PJ, Prenen H.

Ann Gastroenterol. 2018 Mar-Apr;31(2):140-150. doi: 10.20524/aog.2018.0224. Epub 2018 Jan 8. Review.


Cytoreductive surgery and Hyperthermic intra-operative peritoneal chemotherapy with Cisplatin for gastric peritoneal Carcinomatosis Monocentric phase-2 nonrandomized prospective clinical trial.

Topal B, Demey K, Topal H, Jaekers J, Van Cutsem E, Vandecaveye V, Sagaert X, Prenen H.

BMC Cancer. 2017 Nov 17;17(1):771. doi: 10.1186/s12885-017-3730-6.


Integrating geriatric assessment in the first line chemotherapy treatment in older patients with metastatic colorectal cancer: Results of a prospective observational cohort study (AVAPLUS).

Decoster L, Kenis C, Naessens B, Houbier G, De Man M, Lambrecht G, Monsaert E, Moons V, Vergauwe P, Prenen H, Van Cutsem E, Wildiers H.

J Geriatr Oncol. 2018 Mar;9(2):93-101. doi: 10.1016/j.jgo.2017.10.002. Epub 2017 Nov 10.


The effectiveness of intravenous iron for iron deficiency anemia in gastrointestinal cancer patients: a retrospective study.

Verhaeghe L, Bruyneel L, Stragier E, Ferrante M, Dierickx D, Prenen H.

Ann Gastroenterol. 2017;30(6):654-663. doi: 10.20524/aog.2017.0189. Epub 2017 Sep 6.


Survival Outcomes in Patients With RAS Wild Type Metastatic Colorectal Cancer Classified According to Köhne Prognostic Category and BRAF Mutation Status.

Siena S, Rivera F, Taieb J, Peeters M, Prenen H, Koukakis R, Demonty G, Köhne CH.

Clin Colorectal Cancer. 2018 Mar;17(1):50-57.e8. doi: 10.1016/j.clcc.2017.09.006. Epub 2017 Sep 28.


Is There Merit for MET-Targeted Therapies in Gastroesophageal Cancer?

Mazzone M, Finisguerra V, Prenen H.

JAMA Oncol. 2018 Jan 1;4(1):131-132. doi: 10.1001/jamaoncol.2017.2725. No abstract available.


Radiological imaging markers predicting clinical outcome in patients with metastatic colorectal carcinoma treated with regorafenib: post hoc analysis of the CORRECT phase III trial (RadioCORRECT study).

Ricotta R, Verrioli A, Ghezzi S, Porcu L, Grothey A, Falcone A, Van Cutsem E, Argilés G, Adenis A, Ychou M, Barone C, Bouché O, Peeters M, Humblet Y, Mineur L, Sobrero AF, Hubbard JM, Cremolini C, Prenen H, Tabernero J, Jarraya H, Mazard T, Deguelte-Lardiere S, Papadimitriou K, Van den Eynde M, Pastorino A, Redaelli D, Bencardino K, Funaioli C, Amatu A, Carlo-Stella G, Torri V, Sartore-Bianchi A, Vanzulli A, Siena S.

ESMO Open. 2017 Feb 13;1(6):e000111. doi: 10.1136/esmoopen-2016-000111. eCollection 2016.


Prolonged release oxycodone and naloxone treatment counteracts opioid-induced constipation in patients with severe pain compared to previous analgesic treatment.

Koopmans-Klein G, Van Op den Bosch J, van Megen Y, Prenen H, Huygen F, Mancini I.

Curr Med Res Opin. 2017 Dec;33(12):2217-2227. doi: 10.1080/03007995.2017.1367276. Epub 2017 Sep 11.


A new intraductal radiofrequency ablation device for inoperable biliopancreatic tumors complicated by obstructive jaundice: the IGNITE-1 study.

Laleman W, van der Merwe S, Verbeke L, Vanbeckevoort D, Aerts R, Prenen H, Van Cutsem E, Verslype C.

Endoscopy. 2017 Oct;49(10):977-982. doi: 10.1055/s-0043-113559. Epub 2017 Jul 21.


Management of adverse events during treatment of gastrointestinal cancers with epidermal growth factor inhibitors.

Hofheinz RD, Segaert S, Safont MJ, Demonty G, Prenen H.

Crit Rev Oncol Hematol. 2017 Jun;114:102-113. doi: 10.1016/j.critrevonc.2017.03.032. Epub 2017 Apr 11. Review.


Safety and efficacy of doxorubicin-eluting superabsorbent polymer microspheres for the treatment of liver metastases from neuroendocrine tumours: preliminary results.

Bonne L, Verslype C, Laenen A, Cornelissen S, Deroose CM, Prenen H, Vandecaveye V, Van Cutsem E, Maleux G.

Radiol Oncol. 2017 Feb 22;51(1):74-80. doi: 10.1515/raon-2017-0007. eCollection 2017 Mar 1.


The mTOR and PP2A Pathways Regulate PHD2 Phosphorylation to Fine-Tune HIF1α Levels and Colorectal Cancer Cell Survival under Hypoxia.

Di Conza G, Trusso Cafarello S, Loroch S, Mennerich D, Deschoemaeker S, Di Matteo M, Ehling M, Gevaert K, Prenen H, Zahedi RP, Sickmann A, Kietzmann T, Moretti F, Mazzone M.

Cell Rep. 2017 Feb 14;18(7):1699-1712. doi: 10.1016/j.celrep.2017.01.051.


Progression of Barrett's esophagus toward esophageal adenocarcinoma: an overview.

Schoofs N, Bisschops R, Prenen H.

Ann Gastroenterol. 2017;30(1):1-6. doi: 10.20524/aog.2016.0091. Epub 2016 Sep 30. Review.


Current and future biomarkers in the treatment of colorectal cancer.

Cuyle PJ, Prenen H.

Acta Clin Belg. 2017 Apr;72(2):103-115. doi: 10.1080/17843286.2016.1262996. Epub 2016 Dec 5. Review.


Expression profiling of budding cells in colorectal cancer reveals an EMT-like phenotype and molecular subtype switching.

De Smedt L, Palmans S, Andel D, Govaere O, Boeckx B, Smeets D, Galle E, Wouters J, Barras D, Suffiotti M, Dekervel J, Tousseyn T, De Hertogh G, Prenen H, Tejpar S, Lambrechts D, Sagaert X.

Br J Cancer. 2017 Jan 3;116(1):58-65. doi: 10.1038/bjc.2016.382. Epub 2016 Nov 24.


Successful application of endoscopic ultrasound-guided fine needle biopsy to establish pancreatic patient-derived tumor xenografts: a pilot study.

Hermans E, Van der Merwe SW, Depreeuw J, Dekervel J, Radaelli E, Roskams T, van Pelt Jos J, Topal B, Verslype C, Prenen H, Van Steenbergen W, Nevens F, Lambrechts D, Amant F.

Endoscopy. 2016 Nov;48(11):1016-1022. Epub 2016 Sep 14.


Macrophage Metabolism Controls Tumor Blood Vessel Morphogenesis and Metastasis.

Wenes M, Shang M, Di Matteo M, Goveia J, Martín-Pérez R, Serneels J, Prenen H, Ghesquière B, Carmeliet P, Mazzone M.

Cell Metab. 2016 Nov 8;24(5):701-715. doi: 10.1016/j.cmet.2016.09.008. Epub 2016 Oct 20.


Preclinical and clinical evaluation of MET functions in cancer cells and in the tumor stroma.

Finisguerra V, Prenen H, Mazzone M.

Oncogene. 2016 Oct 20;35(42):5457-5467. doi: 10.1038/onc.2016.36. Epub 2016 Mar 21. Review.


Relevance of Geriatric Assessment in Older Patients With Colorectal Cancer.

Decoster L, Vanacker L, Kenis C, Prenen H, Van Cutsem E, Van Der Auwera J, Van Eetvelde E, Van Puyvelde K, Flamaing J, Milisen K, Lobelle JP, De Grève J, Wildiers H.

Clin Colorectal Cancer. 2017 Sep;16(3):e221-e229. doi: 10.1016/j.clcc.2016.07.010. Epub 2016 Aug 8.


Genome-wide association studies in oesophageal adenocarcinoma and Barrett's oesophagus: a large-scale meta-analysis.

Gharahkhani P, Fitzgerald RC, Vaughan TL, Palles C, Gockel I, Tomlinson I, Buas MF, May A, Gerges C, Anders M, Becker J, Kreuser N, Noder T, Venerito M, Veits L, Schmidt T, Manner H, Schmidt C, Hess T, Böhmer AC, Izbicki JR, Hölscher AH, Lang H, Lorenz D, Schumacher B, Hackelsberger A, Mayershofer R, Pech O, Vashist Y, Ott K, Vieth M, Weismüller J, Nöthen MM; Barrett's and Esophageal Adenocarcinoma Consortium (BEACON); Esophageal Adenocarcinoma GenEtics Consortium (EAGLE); Wellcome Trust Case Control Consortium 2 (WTCCC2), Attwood S, Barr H, Chegwidden L, de Caestecker J, Harrison R, Love SB, MacDonald D, Moayyedi P, Prenen H, Watson RGP, Iyer PG, Anderson LA, Bernstein L, Chow WH, Hardie LJ, Lagergren J, Liu G, Risch HA, Wu AH, Ye W, Bird NC, Shaheen NJ, Gammon MD, Corley DA, Caldas C, Moebus S, Knapp M, Peters WHM, Neuhaus H, Rösch T, Ell C, MacGregor S, Pharoah P, Whiteman DC, Jankowski J, Schumacher J.

Lancet Oncol. 2016 Oct;17(10):1363-1373. doi: 10.1016/S1470-2045(16)30240-6. Epub 2016 Aug 12.


Germline variation in inflammation-related pathways and risk of Barrett's oesophagus and oesophageal adenocarcinoma.

Buas MF, He Q, Johnson LG, Onstad L, Levine DM, Thrift AP, Gharahkhani P, Palles C, Lagergren J, Fitzgerald RC, Ye W, Caldas C, Bird NC, Shaheen NJ, Bernstein L, Gammon MD, Wu AH, Hardie LJ, Pharoah PD, Liu G, Iyer P, Corley DA, Risch HA, Chow WH, Prenen H, Chegwidden L, Love S, Attwood S, Moayyedi P, MacDonald D, Harrison R, Watson P, Barr H, deCaestecker J, Tomlinson I, Jankowski J, Whiteman DC, MacGregor S, Vaughan TL, Madeleine MM.

Gut. 2017 Oct;66(10):1739-1747. doi: 10.1136/gutjnl-2016-311622. Epub 2016 Aug 2.


The impact of frailty on postoperative outcomes in individuals aged 65 and over undergoing elective surgery for colorectal cancer: A systematic review.

Fagard K, Leonard S, Deschodt M, Devriendt E, Wolthuis A, Prenen H, Flamaing J, Milisen K, Wildiers H, Kenis C.

J Geriatr Oncol. 2016 Nov;7(6):479-491. doi: 10.1016/j.jgo.2016.06.001. Epub 2016 Jun 21. Review.


Tenckhoff tunneled peritoneal catheter placement in the palliative treatment of malignant ascites: technical results and overall clinical outcome.

Maleux G, Indesteege I, Laenen A, Verslype C, Vergote I, Prenen H.

Radiol Oncol. 2016 Feb 7;50(2):197-203. doi: 10.1515/raon-2016-0002. eCollection 2016 Jun 1.


Gastric cancer.

Van Cutsem E, Sagaert X, Topal B, Haustermans K, Prenen H.

Lancet. 2016 Nov 26;388(10060):2654-2664. doi: 10.1016/S0140-6736(16)30354-3. Epub 2016 May 5. Review.


Use of biologics and chemotherapy in patients with inflammatory bowel diseases and cancer.

Jauregui-Amezaga A, Vermeire S, Prenen H.

Ann Gastroenterol. 2016 Apr-Jun;29(2):127-36. doi: 10.20524/aog.2016.0004. Review.


Comparison of multiple protein extraction buffers for GeLC-MS/MS proteomic analysis of liver and colon formalin-fixed, paraffin-embedded tissues.

Broeckx V, Boonen K, Pringels L, Sagaert X, Prenen H, Landuyt B, Schoofs L, Maes E.

Mol Biosyst. 2016 Feb;12(2):553-65. doi: 10.1039/c5mb00670h.


Yttrium-90 radioembolization for the treatment of chemorefractory colorectal liver metastases: Technical results, clinical outcome and factors potentially influencing survival.

Maleux G, Deroose C, Laenen A, Verslype C, Heye S, Haustermans K, De Hertogh G, Sagaert X, Topal B, Aerts R, Prenen H, Vanbeckevoort D, Vandecaveye V, Van Cutsem E.

Acta Oncol. 2016;55(4):486-95. doi: 10.3109/0284186X.2015.1101151. Epub 2015 Dec 1.


Expression of FOXP1 and Colorectal Cancer Prognosis.

De Smedt L, Palmans S, Govaere O, Moisse M, Boeckx B, De Hertogh G, Prenen H, Van Cutsem E, Tejpar S, Tousseyn T, Sagaert X.

Lab Med. 2015 Fall;46(4):299-311. doi: 10.1309/LM7IHV2NJI1PHMXC.


Phospholipase C gamma 1 (PLCG1) R707Q mutation is counterselected under targeted therapy in a patient with hepatic angiosarcoma.

Prenen H, Smeets D, Mazzone M, Lambrechts D, Sagaert X, Sciot R, Debiec-Rychter M.

Oncotarget. 2015 Nov 3;6(34):36418-25. doi: 10.18632/oncotarget.5503.


Oncological emergencies associated with gastrointestinal tumors.

Prenen K, Prenen H.

Ann Gastroenterol. 2015 Oct-Dec;28(4):426-30. Review.


Intrahepatic therapy for liver-dominant metastatic colorectal cancer.

De Groote K, Prenen H.

World J Gastrointest Oncol. 2015 Sep 15;7(9):148-52. doi: 10.4251/wjgo.v7.i9.148. Review.


PHD1 regulates p53-mediated colorectal cancer chemoresistance.

Deschoemaeker S, Di Conza G, Lilla S, Martín-Pérez R, Mennerich D, Boon L, Hendrikx S, Maddocks OD, Marx C, Radhakrishnan P, Prenen H, Schneider M, Myllyharju J, Kietzmann T, Vousden KH, Zanivan S, Mazzone M.

EMBO Mol Med. 2015 Oct;7(10):1350-65. doi: 10.15252/emmm.201505492.


A phase I/II, open-label, randomised study of nintedanib plus mFOLFOX6 versus bevacizumab plus mFOLFOX6 in first-line metastatic colorectal cancer patients.

Van Cutsem E, Prenen H, D'Haens G, Bennouna J, Carrato A, Ducreux M, Bouché O, Sobrero A, Latini L, Staines H, Oum'Hamed Z, Dressler H, Studeny M, Capdevila J.

Ann Oncol. 2015 Oct;26(10):2085-91. doi: 10.1093/annonc/mdv286. Epub 2015 Aug 12.


Microsatellite instable vs stable colon carcinomas: analysis of tumour heterogeneity, inflammation and angiogenesis.

De Smedt L, Lemahieu J, Palmans S, Govaere O, Tousseyn T, Van Cutsem E, Prenen H, Tejpar S, Spaepen M, Matthijs G, Decaestecker C, Moles Lopez X, Demetter P, Salmon I, Sagaert X.

Br J Cancer. 2015 Jul 28;113(3):500-9. doi: 10.1038/bjc.2015.213. Epub 2015 Jun 11.


Phase I study of FOLFIRI plus pimasertib as second-line treatment for KRAS-mutated metastatic colorectal cancer.

Macarulla T, Cervantes A, Tabernero J, Roselló S, Van Cutsem E, Tejpar S, Prenen H, Martinelli E, Troiani T, Laffranchi B, Jego V, von Richter O, Ciardiello F.

Br J Cancer. 2015 Jun 9;112(12):1874-81. doi: 10.1038/bjc.2015.144. Epub 2015 May 19.


MET is required for the recruitment of anti-tumoural neutrophils.

Finisguerra V, Di Conza G, Di Matteo M, Serneels J, Costa S, Thompson AA, Wauters E, Walmsley S, Prenen H, Granot Z, Casazza A, Mazzone M.

Nature. 2015 Jun 18;522(7556):349-53. doi: 10.1038/nature14407. Epub 2015 May 18.


Randomized trial of TAS-102 for refractory metastatic colorectal cancer.

Mayer RJ, Van Cutsem E, Falcone A, Yoshino T, Garcia-Carbonero R, Mizunuma N, Yamazaki K, Shimada Y, Tabernero J, Komatsu Y, Sobrero A, Boucher E, Peeters M, Tran B, Lenz HJ, Zaniboni A, Hochster H, Cleary JM, Prenen H, Benedetti F, Mizuguchi H, Makris L, Ito M, Ohtsu A; RECOURSE Study Group.

N Engl J Med. 2015 May 14;372(20):1909-19. doi: 10.1056/NEJMoa1414325.


Tumour-educated circulating monocytes are powerful candidate biomarkers for diagnosis and disease follow-up of colorectal cancer.

Hamm A, Prenen H, Van Delm W, Di Matteo M, Wenes M, Delamarre E, Schmidt T, Weitz J, Sarmiento R, Dezi A, Gasparini G, Rothé F, Schmitz R, D'Hoore A, Iserentant H, Hendlisz A, Mazzone M.

Gut. 2016 Jun;65(6):990-1000. doi: 10.1136/gutjnl-2014-308988. Epub 2015 Mar 26.


Iron deficiency in gastrointestinal oncology.

Verraes K, Prenen H.

Ann Gastroenterol. 2015 Jan-Mar;28(1):19-24. Review. No abstract available.


Polymorphisms near TBX5 and GDF7 are associated with increased risk for Barrett's esophagus.

Palles C, Chegwidden L, Li X, Findlay JM, Farnham G, Castro Giner F, Peppelenbosch MP, Kovac M, Adams CL, Prenen H, Briggs S, Harrison R, Sanders S, MacDonald D, Haigh C, Tucker A, Love S, Nanji M, deCaestecker J, Ferry D, Rathbone B, Hapeshi J, Barr H, Moayyedi P, Watson P, Zietek B, Maroo N, Gay L, Underwood T, Boulter L, McMurtry H, Monk D, Patel P, Ragunath K, Al Dulaimi D, Murray I, Koss K, Veitch A, Trudgill N, Nwokolo C, Rembacken B, Atherfold P, Green E, Ang Y, Kuipers EJ, Chow W, Paterson S, Kadri S, Beales I, Grimley C, Mullins P, Beckett C, Farrant M, Dixon A, Kelly S, Johnson M, Wajed S, Dhar A, Sawyer E, Roylance R, Onstad L, Gammon MD, Corley DA, Shaheen NJ, Bird NC, Hardie LJ, Reid BJ, Ye W, Liu G, Romero Y, Bernstein L, Wu AH, Casson AG, Fitzgerald R, Whiteman DC, Risch HA, Levine DM, Vaughan TL, Verhaar AP, van den Brande J, Toxopeus EL, Spaander MC, Wijnhoven BP, van der Laan LJ, Krishnadath K, Wijmenga C, Trynka G, McManus R, Reynolds JV, O'Sullivan J, MacMathuna P, McGarrigle SA, Kelleher D, Vermeire S, Cleynen I, Bisschops R, Tomlinson I, Jankowski J.

Gastroenterology. 2015 Feb;148(2):367-78. doi: 10.1053/j.gastro.2014.10.041. Epub 2014 Nov 5.


Docetaxel plus oxaliplatin with or without fluorouracil or capecitabine in metastatic or locally recurrent gastric cancer: a randomized phase II study.

Van Cutsem E, Boni C, Tabernero J, Massuti B, Middleton G, Dane F, Reichardt P, Pimentel FL, Cohn A, Follana P, Clemens M, Zaniboni A, Moiseyenko V, Harrison M, Richards DA, Prenen H, Pernot S, Ecstein-Fraisse E, Hitier S, Rougier P.

Ann Oncol. 2015 Jan;26(1):149-56.


Postgastrectomy protein-losing cytomegalovirus jejunitis in an immunocompromised patient.

Roelandt P, Poels H, Meeus E, Van Cutsem E, Prenen H.

Endoscopy. 2014;46 Suppl 1 UCTN:E427-8. doi: 10.1055/s-0034-1377433. Epub 2014 Oct 14. No abstract available.


Endothelial deficiency of L1 reduces tumor angiogenesis and promotes vessel normalization.

Magrini E, Villa A, Angiolini F, Doni A, Mazzarol G, Rudini N, Maddaluno L, Komuta M, Topal B, Prenen H, Schachner M, Confalonieri S, Dejana E, Bianchi F, Mazzone M, Cavallaro U.

J Clin Invest. 2014 Oct;124(10):4335-50. doi: 10.1172/JCI70683. Epub 2014 Aug 26.


Randomized phase Ib/II trial of rilotumumab or ganitumab with panitumumab versus panitumumab alone in patients with wild-type KRAS metastatic colorectal cancer.

Van Cutsem E, Eng C, Nowara E, Swieboda-Sadlej A, Tebbutt NC, Mitchell E, Davidenko I, Stephenson J, Elez E, Prenen H, Deng H, Tang R, McCaffery I, Oliner KS, Chen L, Gansert J, Loh E, Smethurst D, Tabernero J.

Clin Cancer Res. 2014 Aug 15;20(16):4240-50. doi: 10.1158/1078-0432.CCR-13-2752. Epub 2014 Jun 11.


Molecular genetics of colorectal cancer.

Bogaert J, Prenen H.

Ann Gastroenterol. 2014;27(1):9-14. Review.


Phase II open-label study to assess efficacy and safety of lenalidomide in combination with cetuximab in KRAS-mutant metastatic colorectal cancer.

Siena S, Van Cutsem E, Li M, Jungnelius U, Romano A, Beck R, Bencardino K, Elez ME, Prenen H, Sanchis M, Sartore-Bianchi A, Tejpar S, Gandhi A, Shi T, Tabernero J.

PLoS One. 2013 Nov 11;8(11):e62264. doi: 10.1371/journal.pone.0062264. eCollection 2013.


Cancer risk in immune-mediated inflammatory diseases (IMID).

Beyaert R, Beaugerie L, Van Assche G, Brochez L, Renauld JC, Viguier M, Cocquyt V, Jerusalem G, Machiels JP, Prenen H, Masson P, Louis E, De Keyser F.

Mol Cancer. 2013 Aug 29;12(1):98. doi: 10.1186/1476-4598-12-98. Review.


Proteomic analysis of formalin-fixed paraffin-embedded colorectal cancer tissue using tandem mass tag protein labeling.

Maes E, Valkenborg D, Mertens I, Broeckx V, Baggerman G, Sagaert X, Landuyt B, Prenen H, Schoofs L.

Mol Biosyst. 2013 Nov;9(11):2686-95. doi: 10.1039/c3mb70177h.


Role of targeted agents in metastatic colorectal cancer.

Prenen H, Vecchione L, Van Cutsem E.

Target Oncol. 2013 Jun;8(2):83-96. doi: 10.1007/s11523-013-0281-x. Epub 2013 May 5. Review.


Administration of imatinib mesylate in rats impairs the neonatal development of intramuscular interstitial cells in bladder and results in altered contractile properties.

Gevaert T, Hutchings G, Everaerts W, Prenen H, Roskams T, Nilius B, De Ridder D.

Neurourol Urodyn. 2014 Apr;33(4):461-8. doi: 10.1002/nau.22415. Epub 2013 Apr 24.


Supplemental Content

Loading ...
Support Center